• NCVHS Issues Request for Comment on CAQH CORE and X12 Proposals.
• CMS Administrator to Hold National Stakeholder Call.
• ONC to Host Health IT Certification Program Developer Roundtable.
• ONC Reminder: 2015 Cures Update Requirements Compliance Deadline.
• ONC Informs CMS Ruling on Hospital Measures for Public Health and Health Equity Reporting.
• ONC Discusses Standards that Support SDOH Data Capture.
• CMS Reminds Providers that 2022 APM Incentive Payment Action Needed by November 1.
• New Research Suggests Patient Outcome Prediction Tool May Improve Clinical Decision-Making and Patient Outcomes.

OSTP, in Partnership with ONC, Seeks Input on Optimizing Data Capture for Clinical Trials

The COVID-19 pandemic demonstrated the need for a coordinated clinical trials enterprise, one that can swiftly characterize emerging viral threats and evaluate the effectiveness of vaccines, therapeutics, and other countermeasures across a diversity of trial participants. In response, the Biden-Harris Administration released the National Biodefense Strategy, which calls for a U.S. clinical trials infrastructure “ready to administer candidate countermeasures to participants within 14 days after the identification of a viable countermeasure.” In support of this effort, the White House Office of Science & Technology Policy (OSTP), in coordination with the National Security Council, issued a Request for Information (RFI) on October 26 seeking input from the public about how a coordinated clinical research system can be deployed in the event of an emerging disease outbreak.